This is a routine procedural loss with no material impact on Teva's stock. The underlying antitrust case continues, monitor for summary judgment motions or trial dates, which would be the next material catalysts.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 24 $30.81entry
- T+1 · 4mo ago +0.88%α +0.85% · $31.08
- T+5 · 4mo ago +13.63%α +12.54% · $35.01
- T+20 · 3mo ago +21.19%α +17.57% · $37.34
- T+60 · 29d ago +34.08%α +30.09% · $41.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teva lost a discovery dispute in its antitrust/physician-payment lawsuit against Corcept Therapeutics. The court denied Teva's motion to compel production of text messages from Corcept's DOJ production, finding Teva failed to show the messages were relevant or proportional. This is a minor procedural setback in a pending case, no damages, no injunction, no change to the underlying claims.
Court Ruling Details
Key Facts
- Teva sued Corcept alleging anticompetitive physician payments to induce prescriptions of Korlym over Teva's generic mifepristone.
- Teva moved to compel Corcept to produce text messages from a prior DOJ production regarding physician payments.
- The court denied the motion, ruling Teva did not show the text messages were relevant or proportional to the case.
- The ruling is a discovery dispute resolution, no damages awarded, no injunction issued, no claims dismissed.
- The case (5:24-cv-03567-NW) remains active in the Northern District of California.
Financial Impact
No financial impact, discovery ruling only, no damages or exposure stated.
Risk Factors
- Teva's antitrust claims against Corcept remain pending and could result in damages or injunctive relief if Teva ultimately prevails.
- Corcept's motion practice may delay resolution of the case, extending legal costs and uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-dec579e875-TEVA |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers